A Study to Assess the Pharmacokinetics of Single Escalating Doses of Inhaled GSK961081 DPI (a Dual Pharmacophore) in Healthy Subjects (Part 1) and a Randomised, Double-Blind, Double Dummy, Crossover (Incomplete Block) Study to Assess the Safety, Tolerability, Pharmacodynamics (Pulmonary and Systemic) and Pharmacokinetics of 14 Days Dosing With Inhaled GSK961081 DPI Compared With Placebo and Tiotropium Plus Salmeterol in Patients With COPD (Part 2).

Trial Profile

A Study to Assess the Pharmacokinetics of Single Escalating Doses of Inhaled GSK961081 DPI (a Dual Pharmacophore) in Healthy Subjects (Part 1) and a Randomised, Double-Blind, Double Dummy, Crossover (Incomplete Block) Study to Assess the Safety, Tolerability, Pharmacodynamics (Pulmonary and Systemic) and Pharmacokinetics of 14 Days Dosing With Inhaled GSK961081 DPI Compared With Placebo and Tiotropium Plus Salmeterol in Patients With COPD (Part 2).

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Feb 2017

At a glance

  • Drugs Batefenterol (Primary) ; Salmeterol; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 25 Jul 2013 Results will be presented at the European Respiratory Society Annual Congress in September 2013, according to a Theravance media release.
    • 28 Sep 2011 Results presented at the 21st Annual Congress of the European Respiratory Society.
    • 14 Jul 2008 Status changed to completed, according to a Theravance media release which reported results.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top